Zidebactam sodium salt
Based on 10 publication(s) in Google Scholar
Zidebactam sodium salt (WCK-5107 sodium salt) is a potent β-lactamase inhibitor. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL.
For research use only. We do not sell to patients.
- CAS No.: 1706777-46-9
- Formula: C13H20N5NaO7S
- Molecular Weight:413.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Zidebactam sodium salt
More- Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
- Sci Rep. 2025 Sep 29;15(1):33616. [Abstract]
- Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0077524. [Abstract]
- Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. [Abstract]
- Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0167621. [Abstract]
- J Antimicrob Chemother. 2025 Apr 2;80(4):1137-1140. [Abstract]
- J Antimicrob Chemother. 2023 May 3;78(5):1191-1194. [Abstract]
- Microbiol Spectr. 2022 Feb 23;10(1):e0267821. [Abstract]
- University of Skovde. 2025.
- bioRxiv. 2025 January 21.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
All Beta-lactamase Isoforms
More
Biological Activity
IC50: 0.26±0.06 μg/mL (P. aeruginosa PAO1 PBP2)[2].
Zidebactam sodium salt (WCK-5107 sodium salt) inhibits WT Enterobacteriaceae with a MIC50 of 0.25 mg/L[1].Zidebactam sodium salt (WCK-5107 sodium salt) alone exhibits variable activity when tested against E. coli (MIC50/90 0.12/0.12 mg/L) and Enterobacter spp. (MIC50/90 0.12/0.25 mg/L)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1706777-46-9
-
Molecular Weight 413.38
-
Formula C13H20N5NaO7S
-
SMILES
O=C([C@@H]1CCCNC1)NNC([C@@H]2CC[C@@H]3C[N@]2C(N3OS(=O)(O[Na])=O)=O)=O
-
Synonyms
WCK-5107 sodium salt
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Antibiotics (Basel)
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]2021 Nov 3;10(11):1341. PMID: 34827279
Zidebactam sodium salt purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
time–kill curves of Zidebactam (ZID) (0.5 µg/mL; 24 h) on C. amalonaticus N18 and K. pneumoniae KL 12 SG.
-
Sci Rep
Sporadic cefiderocol resistance in Escherichia coli from the United Arab Emirates involves multifactorial mechanisms reversible by novel beta-lactamase inhibitors. [Abstract]2025 Sep 29;15(1):33616. PMID: 41023121
Zidebactam sodium salt purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Sep 29;15(1):33616. [Abstract]
Zidebactam (0.125-0.5 µg/mL) had a potent antibacterial effect on four E. coli strains.
-
Antimicrob Agents Chemother
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]2024 Nov 6;68(11):e0077524. PMID: 39365068 -
Antimicrob Agents Chemother
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. [Abstract]2023 Jul 18;67(7):e0033923. PMID: 37255469 -
Antimicrob Agents Chemother
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales. [Abstract]2022 Feb 15;66(2):e0167621. PMID: 34807754 -
J Antimicrob Chemother
Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2. [Abstract]2025 Apr 2;80(4):1137-1140. PMID: 39960091 -
J Antimicrob Chemother
In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. [Abstract]2023 May 3;78(5):1191-1194. PMID: 36921067 -
Microbiol Spectr
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate. [Abstract]2022 Feb 23;10(1):e0267821. PMID: 35196805 -
-
Purity & Documentation
References
[1]. Sader HS, et al. WCK 5222 ( cefepime/zidebactam ) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. [Content Brief]
[2]. Moya B, et al. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob Agents Chemother. 2017 May 24;61(6). [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zidebactam sodium salt Related Classifications
HY-120859A Related Classifications
Powered by Bioz